Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

For Early or New-Onset Type 1 Diabetes) is a randomized, placebo-controlled Phase 3 trial intended to enroll approximately 240 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at over 100 study centers throughout Europe and North America. The trial is designed to evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will preserve beta cell function as measured by C-peptide, a surrogate measure of beta cell function. The primary endpoint will be a measurement of C-peptide. For information about DEFEND, please visit www.DefendAgainstDiabetes.com.

About the TTEDD Study

TTEDD is a non-randomized, open-label Phase 2 study intended to enroll approximately 100 patients, age 18 to 45, with autoimmune type 1 diabetes. The purpose of TTEDD is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.

About Otelixizumab'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
(Date:5/21/2013)... The congress of the ERA-EDTA ... the biggest congress in Europe ... are in Istanbul to share ... pioneering studies have been presented: / (1) ... VIA HEMODIALYSATE REDUCES ESA USE" By SFP-iron ...
(Date:5/21/2013)... May 21, 2013 Smarter Security, Inc., ... solutions, today announced that Genzyme, a Sanofi company and ... Door Detective® CL for a multi-use facility in the ... four other Genzyme buildings, this latest order underscores the ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... FL (PRWEB) May 21, 2013 Many ... breakouts as contributor to acne. Recently physicians from ... of mental stress on the skin, and suggested using ... help reduce the chemicals produced from stress that cause ... from the negative feelings acne brings about, stress causes ...
Breaking Biology Technology:Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2
... Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the ... of pixantrone for the treatment of diffuse large B-cell ... Drug Administration,s (the "FDA") Division of Hematologic Products (the ... the PIX-R or PIX 306 trial, will compare a ...
... thigh bones that enable them to support huge loads whilst ... the journal Proceedings of the Royal Society B . ... of new materials based on thigh bone geometry. A ... collected thigh bone samples from British museum collections and zoos, ...
... , BOULDER, Colo.Physicists at the National,Institute of ... in which microwaves communicate with,a vibrating mechanical ... before in,similar experiments. The microscopic,apparatus is a ... control the,motion of a relatively large object ...
Cached Biology Technology:FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5Study of 90 animals' thigh bones reveals how they can efficiently carry loads 2Study of 90 animals' thigh bones reveals how they can efficiently carry loads 3NIST electromechanical circuit sets record beating microscopic 'drum' 2NIST electromechanical circuit sets record beating microscopic 'drum' 3
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2
... a protein implicated in Alzheimer's disease, researchers at UT ... gene responsible for producing the specific protein ?called amyloid-beta ... and greatly reduce the protein's build-up in the brain. ... of Alzheimer's disease. , "The whole point of the ...
... researchers at Duke's Pratt School of Engineering have imaged ... demonstration showed that the probes could give surgeons a ... are performed through tiny "keyhole" incisions. , If the ... lead to more precise and safer endoscopic surgeries, said ...
... University of York have launched a new research project which ... Researchers from the University's Department of Biology are heading the ... cells for use in the repair of bone defects and ... in the UK and across Europe, as well as academics ...
Cached Biology News:DNA gene vaccine protects against harmful protein of Alzheimer's disease 2Rare Tibetan antelope listed as endangered 2Rare Tibetan antelope listed as endangered 3Bones from blood: Scientists aim to break new ground on fractures 2
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: